Q-omics provides the consensus-scored RFPL1S profile across patient tissues and cancer cell-line models. RFPL1S expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RFPL1S is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, RFPL1S RNA expression shows 18,274 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, THCA, and GBM as cancer lineages where RFPL1S shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RFPL1S — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RFPL1S survival associations across molecular data types. RFPL1S RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RFPL1S RNA expression–survival associations across cancer types. High RFPL1S expression shows unfavorable associations in UCEC, LIHC and KIRP, but favorable associations in CHOL, HNSC and LGG. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for RFPL1S RNA expression.
This table summarizes RFPL1S tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RFPL1S. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RFPL1S shows lower tumor expression in THCA and COAD and higher tumor expression in BRCA, KIRC, LIHC and LUSC. The THCA box plot shows higher RFPL1S RNA expression in normal versus tumor tissue (log2 FC = −0.128, t-test p < 0.001).
This table shows molecular features associated with RFPL1S in patient tissues and cancer cell lines. In patient samples, RFPL1S shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RFPL1S RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
